'''Mespirenone''' ([[International Nonproprietary Name|INN]]) (developmental code name '''ZK-94679'''), also known as '''Δ<sup>1</sup>-15β,16β-methylenespironolactone''', is a [[steroid]]al [[antimineralocorticoid]] of the [[spirolactone]] group related to [[spironolactone]] that was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA775|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=775–}}</ref><ref name="pmid3028435">{{cite journal | vauthors = Losert W, Bittler D, Buse M, Casals-Stenzel J, Haberey M, Laurent H, Nickisch K, Schillinger E, Wiechert R | title = Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists | journal = Arzneimittelforschung | volume = 36 | issue = 11 | pages = 1583–600 | year = 1986 | pmid = 3028435 | doi = | url = }}</ref> Animal research found that it was 3.3-fold more potent as an antimineralocorticoid relative to spironolactone.<ref>{{cite book|title=Arzneimittel-Forschung|url=https://books.google.com/books?id=QtcTAQAAMAAJ|year=1991|publisher=Editio Cantor}}</ref> In addition to its antimineralocorticoid properties, mespirenone is also a [[progestogen]], [[antigonadotropin]], and [[antiandrogen]].<ref name="pmid3028435" /><ref name="pmid3245852">{{cite journal | vauthors = Nishino Y, Schröder H, el Etreby MF | title = Experimental studies on the endocrine side effects of new aldosterone antagonists | journal = Arzneimittelforschung | volume = 38 | issue = 12 | pages = 1800–5 | year = 1988 | pmid = 3245852 | doi = | url = }}</ref> It is 2- to 3-fold as potent as spironolactone as a progestogen and antigonadotropin but its antiandrogenic activity is markedly reduced and weak (though still of significance) in comparison.<ref name="pmid3245852" /><ref name="pmid1996630">{{cite journal | vauthors = Opoku J, Kalimi M, Agarwal M, Qureshi D | title = Effect of a new mineralocorticoid antagonist mespirenone on aldosterone-induced hypertension | journal = Am. J. Physiol. | volume = 260 | issue = 2 Pt 1 | pages = E269–71 | year = 1991 | pmid = 1996630 | doi = | url = }}</ref> Mespirenone is also a [[potency (pharmacology)|potent]] and specific [[enzyme inhibitor]] of [[18-hydroxylase]] and thus of [[mineralocorticoid]] [[biosynthesis]].<ref name="pmid1796922">{{cite journal | vauthors = Weindel K, Lewicka S, Vecsei P | title = Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro | journal = Arzneimittelforschung | volume = 41 | issue = 9 | pages = 946–9 | year = 1991 | pmid = 1796922 | doi = | url = }}</ref> The drug was under development by [[Schering AG|Schering]] (now [[Bayer Schering Pharma]]) and reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s but was discontinued in 1989.<ref name="OttowWeinmann2008">{{cite book|author1=Eckhard Ottow|author2=Hilmar Weinmann|title=Nuclear Receptors as Drug Targets|url=https://books.google.com/books?id=iATfLbPgRugC&pg=PA410|date=8 September 2008|publisher=John Wiley & Sons|isbn=978-3-527-62330-3|pages=410–}}</ref>
